Asparagine metabolism in tumors is linked to poor survival in females with colorectal cancer: A cohort study

Xinyi Shen¹, Yuping Cai^{2,3}, Lingeng Lu¹, Huang Huang², Hong Yan², Philip B. Paty⁴, Engjel Muca⁴, Nita Ahuja⁷, Yawei Zhang^{2,5,6}, Caroline H. Johnson^{2*}, Sajid A. Khan^{7*}

¹ Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven, CT USA

² Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT USA

³ Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China

⁴ Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

⁵ Department of Surgery, Yale University School of Medicine, New Haven, CT, USA

⁶ National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

⁷ Department of Surgery, Division of Surgical Oncology, Yale University School of Medicine, New Haven, CT, USA

*Corresponding Authors

Caroline H. Johnson, Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT, 06520, USA. Phone:203-785-2882; E-mail: caroline.johnson@yale.edu

Sajid A. Khan, Department of Surgery, Division of Surgical Oncology, Yale University School of Medicine, New Haven, CT, 06520, USA. Phone:203-337-8507; E-mail: sajid.khan@yale.edu

Disclosures

The authors declare no conflicts of interest.

Abstract

Background or Purpose

The interplay between the sex-specific differences in tumor metabolome and colorectal cancer (CRC) prognosis has never been studied and represents an opportunity to improve patient outcomes. This study aims to examine the link between tumor metabolome and prognosis by sex for CRC patients.

Methods

Using untargeted metabolomics analysis, abundances of 91 metabolites were obtained from primary tumor tissues from 197 patients (N=95 females, N=102 males) after surgical colectomy for stage I-III CRC. Cox Proportional Hazards (PH) regression models were applied to estimate the associations between tumor metabolome and 5-year overall survival (OS) and 5-year recurrence-free survival (RFS), and their interactions with sex.

Results

Eleven metabolites had significant sex differences in their associations with 5-year OS, and five metabolites for 5-year RFS ($P_{\text{interaction}} < .05$). The metabolites asparagine and serine had sex interactions for both OS and RFS. Furthermore, sex-specific differences were found in the associations between prognosis and metabolic pathways. Notably, in the asparagine synthetase (ASNS)-catalyzed asparagine synthesis pathway, asparagine was associated with substantially poorer OS (hazard ratio [HR] = 6.39, 95% confidence interval [CI] = 1.78-22.91, $P = .004$) and RFS (HR = 4.36, 95% CI = 1.39-13.68, $P = .01$) for female patients only ($P_{\text{interaction, OS}} = .02$,

$P_{\text{interaction, RFS}} = .003$). Similar prognostic disadvantages in females were seen in lysophospholipid and polyamine synthesis.

Discussion or Conclusions

Unique metabolite profiles indicated increased asparagine synthesis was associated with poorer prognosis for females only, providing insights into precision medicine for CRC treatment stratified by sex.

Introduction

According to the U.S. Centers for Disease Control and Detection (CDC), colorectal cancer (CRC) was the third leading cause of cancer-related deaths in the United States in 2021¹. Prognosis is partly dependent on stage at presentation according to TNM classification system based on the American Joint Committee on Cancer (AJCC)² and Union for International Cancer Control (UICC)³. Additional clinicopathologic variables can also impact survival such as primary tumor location^{4,5}, body mass index (BMI)⁶, and diabetes conditions⁷.

The application of biomarkers in a clinical context has potential to improve prognosis based on gene mutations^{8,9}, microRNAs¹⁰, and DNA methylation^{11,12}. During the last decade, cancer studies have benefited from the implementation of metabolomics¹³. CRC metabolomic studies have shown the correlation of certain metabolite profiles to cancer survival and recurrence using biological samples of urine and tissue¹⁴. Some plasma metabolites are associated with recurrence in stage II and III patients¹⁵, showing the potential value of metabolomics in finding prognostic biomarkers of CRC.

In addition, sex-related differences in CRC prognosis have become increasingly important in cancer research^{16,17}. Female patients have a higher prevalence of right-sided colon cancer (RCC), which is associated with poorer overall survival (OS)^{18,19}. However, male CRC patients have a survival disadvantage in most subgroups by anatomic location and age²⁰. At present, female and male patients do not receive different sex-specific therapies.

Previously, our untargeted metabolomics analyses in a large series of CRC tumor tissues revealed sex-specific metabolic subphenotypes that could influence tumor progression and response to therapeutics²¹. Important metabolic pathways in these subphenotypes included

asparagine synthesis, energy production (glycolysis and pentose phosphate pathway (PPP)), lysophospholipid synthesis, methionine metabolism, and polyamine synthesis²¹. Particularly, female patients with RCC showed increased asparagine levels²¹, which can be produced intracellularly by an ATP- and glutamine-dependent reaction catalyzed by asparagine synthetase (ASNS)²². By examining The Cancer Genome Atlas (TCGA) data, we discovered that high ASNS expression was associated with poorer OS for female CRC patients²¹. Additionally, increased ASNS expression has been linked to aggressive tumors and poorer prognosis in other cancer types^{23,24}. These findings suggest that sex plays a vital role in CRC prognosis together with the covariates of metabolism and anatomic tumor location. A clear understanding of these sex-specific metabolic differences represents a golden opportunity to prolong the survival of CRC patients.

In this study, we examine whether there is a link between CRC tumor metabolites and prognosis stratified by sex of the patient. This is the first study to reveal that sex-related differences exist in primary tumor metabolite profiles that are associated with OS and recurrence-free survival (RFS) in patients who have undergone curative intent colectomy. We also identify metabolic pathways which are associated with poor survival only in female CRC.

Methods

Sample Collection and Metabolite Measurements

Fresh frozen tumor tissue samples were acquired after curative intent colectomy for patients (N=197) with RCCs (cecum, ascending colon and hepatic flexure) or LCCs (splenic flexure, descending colon, sigmoid, rectosigmoid) with stage I-III CRC (1991-2000). No patients received neoadjuvant chemotherapy. Finally, abundances of 91 metabolites were obtained as

published previously²¹. Metabolites were extracted and analyzed by hydrophilic interaction liquid chromatography mass spectrometry (HILIC-MS) and reverse phase liquid chromatography mass spectrometry (RPLC-MS)-based metabolomics as previously described²¹. More information is presented in S1 Text. Yale University IRB determined that this study was not considered Human Subjects Research and did not require IRB review (IRB/HSC# 1612018746).

Statistical Analysis

We included age, sex, anatomic primary tumor location, chemotherapy history, and clinical stage as covariates. Missing values of metabolites abundances were replaced using median imputation. Multivariable Cox proportional hazard (Cox PH) regression models were constructed to evaluate the associations between prognosis with individual metabolite abundance per standard deviation (SD) increase on a log₂-scale, adjusted for covariates in either all patients or stratified by sex. Assessment of associations between sex-specific metabolic pathways and prognosis was conducted by multivariate Cox PH models that included important metabolites involved in these pathways. Sex-specific difference was examined in multivariate Cox PH models by including an interaction between sex and the metabolite. 5-year OS, 5-year RFS were calculated. Due to the absence of death events in female patients at clinical stage I, we recoded the clinical stages I and II as “early stage”, and III as “late stage”. Patients with adjuvant chemotherapy were coded as having chemotherapy history. Survival analyses were conducted using package “survival” in R (version 4.0.4). A 2-sided *P* value less than .05 was considered statistically significant.

Results

Population Characteristics

Baseline characteristics of 197 patients (N=102 males, N=95 females), including 5-year OS and 5-year RFS, are provided in Table 1. Median follow-up time since date of surgery was 74.8 months (0.1-169.2). Older age, administration of chemotherapy, and advanced clinical stage were inversely related to OS (Table 1). Each subgroup by anatomic tumor location and clinical stage, demographic characteristics including race/ethnicity are displayed in S1 Table. Prognosis among different subgroups is shown in S2 Table.

Sex-specific differences in the associations between individual metabolite abundances and CRC prognosis

Eighteen metabolites were significantly associated with OS in males or females or in both sexes (S3 Table), adjusted for anatomic location, clinical stage, chemotherapy history, and age, similarly 25 metabolites had significant correlations with RFS (S4 Table). Only carnitine and hypoxanthine remained significantly associated with RFS for males after false discovery rate (FDR) adjustment.

Multivariate Cox PH models on single metabolites and their associations with OS or RFS revealed dichotomous findings by sex. Fig 1 presents the metabolites (adenosine, asparagine, citrulline, glycerol 3-phosphate (Gro3P), lysophosphatidylcholine (LysoPC)(16:0), ornithine, succinate, threonine, UDP-D-glucose, uracil, and xanthosine) that had sex differences in their associations with CRC prognosis ($P_{\text{interaction}} < .05$). Among these 11 metabolites, succinate was significantly associated with improved OS for female patients ($HR_{OS} = 0.35$, 95% CI=0.12-0.99;

$P = .047$), while it was associated with poorer OS for males ($HR_{OS} = 1.91$, 95% CI=1.23-2.96, $P = .004$) (Fig 1A). Five metabolites (argininosuccinic acid, asparagine, creatinine, hypoxanthine, and serine) showed significance for RFS and sex-specific differences (Fig 1B). Of these metabolites, asparagine exhibited sex differences for both OS and RFS ($P_{interaction,OS} = .03$, $P_{interaction,RFS} = .007$), and similarly for serine ($P_{interaction,OS} = .04$, $P_{interaction,RFS} = .01$) (S3 and S4 Table). Asparagine was significantly associated with better CRC prognosis in males ($HR_{OS} = 0.72$, 95% CI=0.54-0.96, $P = .03$; $HR_{RFS} = 0.74$, 95% CI=0.56-0.97, $P = .03$), while its associations with worse prognosis in females trended towards significance ($P_{OS} = .13$, $P_{RFS} = .09$, S3 and S4 Table). Similarly, serine was significantly associated with better prognosis in males ($HR_{OS} = 0.55$, 95% CI=0.37-0.81, $P = .002$. $HR_{RFS} = 0.57$, 95% CI=0.40-0.83, $P = .003$), while it has no significant associations with prognosis in females (S3 and S4 Table).

Sex-specific Differences in CRC Prognosis Associated with Asparagine Synthesis

We examined sex-specific associations between the ASNS-catalyzed asparagine synthesis pathway and CRC prognosis (S5 and S6 Table). Significant interactions with sex were detected in associations between asparagine abundance and both OS and RFS ($P_{interaction,OS} = .02$, $P_{interaction,RFS} = .003$) as summarized as Model 1, where asparagine abundance was treated as a continuous variable (Table 2). In Model 1, asparagine was significantly associated with poor OS ($HR_{OS} = 6.39$, 95% CI=1.78-22.91, $P = .004$) and poor RFS ($HR_{RFS} = 4.36$, 95% CI=1.39-13.68, $P = .01$) only in females, while asparagine was only significantly associated with better OS only in males ($HR_{OS} = 0.57$, 95% CI=0.36-0.91, $P = .02$) after adjustment for clinical stages,

chemotherapy history, age, anatomic location, and other crucial metabolites involved in ASNS expression (Table 2).

An additional multivariate Cox PH regression model was built; Model 2, where asparagine abundance was dichotomized to low levels and high levels. There was a significant interaction between sex and dichotomized asparagine levels for RFS and a similar interaction that was approaching significance for OS (Table 2) ($P_{\text{interaction,OS}} = .052$, $P_{\text{interaction,RFS}} = .03$).

Fig 2 displays the Cox adjusted survival curves for dichotomized asparagine levels based on Model 2, illustrating that female CRC patients with a high level of ASNS-catalyzed asparagine had significantly poorer OS (Fig 2A) and poorer RFS (Fig 2C) compared with female patients with a low level. Strikingly, levels of asparagine were not associated with OS (Fig 2B) or RFS (Fig 2D) for male CRC patients.

Sex-Specific Differences in CRC Prognosis Associated with Glycolysis and the Pentose Phosphate Pathway

Considering glycolysis and the PPP metabolism, the association between Gro3P and OS for females trended towards significance ($P = .08$), and there was no association in males ($P = .76$) (S8 Table). Gro3P was significantly associated with a lower risk of 5-year recurrence only for males ($\text{HR}_{\text{RFS}} = 0.27$, 95% CI=0.08-0.88, $P = .03$), though no sex differences were detected ($P_{\text{interaction}} = .25$) (S7 and S8 Table).

Sex-Specific Differences in CRC Prognosis Associated with

Lysophospholipid Synthesis

We analyzed the relationships between CRC prognosis and important metabolites involved in lysophospholipid synthesis. The interactions between sex and LysoPC (16:0), LysoPC (18:1), lysophosphatidylethanolamine (LysoPE) (18:0), and LysoPE (22:5) in the association with OS were significant (S9 Table). In the multivariate analysis on OS for lysophospholipids synthesis by sex, LysoPC (16:0) was associated with poor OS only for females ($HR_{OS} = 2.07$, 95% CI=1.06-4.07, $P = .03$), while it was not significantly associated with OS for males ($P = .32$) (S10 Table). In the models of RFS for lysophospholipid synthesis by sex, LysoPE (22:5) presented a robust trend toward a significant sex difference in its association with RFS ($P_{interaction} = .052$, S9 Table). LysoPE (22:5) was associated with increased risks of 5-year recurrence of CRC for females ($HR_{RFS} = 5.38$, 95% CI=1.02-28.42, $P = .048$), while it was associated with reduced risk of recurrence for males ($HR_{RFS} = 0.10$, 95% CI=0.02-0.62, $P = .01$) (S10 Table).

Sex-specific Differences in CRC Prognosis Associated with

Methionine Metabolism

Analysis of methionine metabolism for all patients indicated that serine favored better OS ($HR_{OS} = 0.56$, 95% CI=0.34-0.92, $P = .02$) and RFS ($HR_{RFS} = 0.49$, 95% CI=0.29-0.83, $P = .008$) (S11 Table). After further stratification by sex, serine was associated with better OS in males ($HR_{RFS} = 0.37$, 95% CI=0.19-0.72, $P = .004$) and improved RFS in males as well ($HR_{RFS} = 0.49$, 95% CI=0.24-0.98, $P = .04$), while its associations with CRC prognosis in females were not significant (S12 Table). The interaction between serine and sex in terms of OS and RFS were

both significant ($P_{\text{interaction,OS}} = .04$, $P_{\text{interaction,RFS}} = .045$, S11 Table). Methionine had a significant sex interaction (S11 Table), but it was not significantly associated with OS or RFS in either sex (S12 Table). The additional metabolites in this pathway did not have significant sex interactions (S11 Table).

Sex-specific Differences in CRC Prognosis Associated with Polyamine Synthesis

Lastly, we examined metabolites involved in polyamine synthesis. Arginine had a marked trend towards a significant sex interaction with OS ($P_{\text{interaction}} = 0.07$), and a significant sex interaction for RFS ($P_{\text{interaction}} = .04$) (S13 Table). Further stratified by sex, arginine was associated with worse OS only for females ($\text{HR}_{\text{OS}} = 5.63$, 95% CI=1.33-23.78, $P = .02$), while its association with OS in males was not significant ($P = .87$) (S14 Table). For RFS, arginine was associated with higher risks of 5-year CRC recurrence only for females ($\text{HR}_{\text{RFS}} = 3.22$, 95% CI=1.14-9.13, $P = .03$) while it had no significant association with RFS for males ($P = .24$) (S14 Table). Citrulline suggested significant sex interactions with both OS and RFS ($P_{\text{interaction,OS}} = .002$, $P_{\text{interaction,RFS}} = .02$) (S13 Table): it had a significant association with poorer OS for females ($\text{HR}_{\text{OS}} = 2.57$, 95% CI=1.04-6.33, $P = .04$) but not for males ($P = .18$), while it was not significantly associated with RFS in either sex (S14 Table). Other critical metabolites in polyamine synthesis did not have significant sex interactions (S13 Table).

Discussion

To our knowledge, this is the first study to show that sex-specific differences in the CRC tumor metabolome are linked to prognosis. It is also the first application of a novel approach to

examine metabolic pathways and their associations to CRC prognosis. By applying state of the art mass spectrometry to fresh frozen specimens acquired operatively in a large colorectal biorepository, we show that females have a distinct metabolite profile, underscored by asparagine metabolism, that correlates with prognosis after surgical colectomy. This suggests that females and males have unique colorectal tumor metabolism which contributes to sex-specific clinical outcomes.

Our study revealed that 11 tumor metabolites were associated with CRC 5-year OS and five metabolites for 5-year RFS, and these associations were sex-specific. Asparagine and serine were associated with both 5-year OS and 5-year RFS in a sex-specific manner. Further examination of asparagine within the *de novo* asparagine synthesis pathway (catalyzed by ASNS), showed consistently poor OS and RFS with high asparagine abundance for females. This supports previous findings revealing poor female survival and high *ASNS* expression from the TCGA²¹. In addition, we previously hypothesized that asparagine is linked to tumor aggressiveness in females with RCCs as it correlates with increased threonine and serine uptake, which indicates aggressive tumor phenotypes²¹. *ASNS*-catalyzed asparagine production has also been shown to be crucial for *in vitro* cancer cell proliferation by amino acid homeostasis²⁵, and the availability of asparagine *in vitro* and *in vivo* propagate the metastatic progression of breast cancer²⁶.

In CRC, SRY-box 12 (*SOX12*) expression promotes cell proliferation and metastasis, and facilitates *ASNS* expression²⁷. In addition, expression of the mutant *KRAS* gene correlates with a marked decrease in aspartate levels and increased asparagine levels due to upregulated *ASNS* expression, which indicated that *ASNS* might be a novel therapeutic target for *KRAS*-mutant CRC^{28,29}. Moreover, *SLC25A22* serves as an essential metabolic regulator for CRC progression³⁰ by promoting the synthesis of aspartate-derived amino acids (asparagine) in *KRAS*-mutant CRC

cells³¹. Furthermore, increased dietary asparagine in animals promotes metastatic progression in breast cancer, and L-asparaginase treatment or dietary asparagine restriction inhibits metastasis³². Hence, both internally produced asparagine and external exposure to asparagine through diet may influence CRC tumor progression. However, a review study pointed out that some studies are contradictory regarding whether ASNS expression favors or inhibits CRC progression³³, while our findings indicate that such inconsistency may attribute to sex differences.

As mentioned, serine associated with both 5-year OS and RFS in a sex-specific manner. Our data showed that serine favored longer OS and RFS in males but independent of prognosis in females. Serine metabolism has been reported to contribute to CRC metabolism and growth³⁴ and enzymes involved in serine synthesis such as phosphoglycerate dehydrogenase (*PHGDH*)³⁵ are found in higher levels in colonic tumor tissue than paired normal tissue³⁶. These studies did not consider sex differences which might lend to a potential sex-specific phenomenon.

Our results indicated that sex significantly modified the associations between lysophospholipid synthesis and CRC prognosis. LysoPC (16:0) was associated with worse OS for females in both individual metabolite analysis and the model for lysophospholipid synthesis. Our previous study identified that multiple LysoPCs and LysoPEs were upregulated in female patients with RCC (stage I) only, suggesting that the higher level of lysophospholipids in women with RCC would promote fatty acid supply that is essential for cancer cell growth at early stages²¹. It has also been discussed that sex-specific estrogen regulation may inhibit CRC cell survival by suppressed triglyceride biosynthesis, a vital lipid marker related to CRC progression¹⁷.

Lastly, sex interacts with the associations between polyamine metabolism and CRC prognosis. Arginine and citrulline was associated with worse RFS and OS respectively for females but not for males. A previous study investigated the L-arginine/nitric oxide (NO) pathway in CRC by

clinical stage, location of a primary tumor, and sex, and they observed elevated arginine levels in LCCs compared with RCCs, and a drop in arginine levels in the early postoperative period in females exclusively³⁷. Arginine and citrulline are important part of the urea cycle³⁸, where ornithine is produced and metabolized into polyamines by ornithine decarboxylase (ODC)³⁹. ODC is a target for inhibition by difluoromethylornithine (DFMO) (an anti-polyamine therapy for colorectal neoplasia)⁴⁰, therefore, some of the polyamine precursors could be important for polyamine treatment responses, where sex can play a role. There are NCI funded cooperative group CRC chemoprevention trials targeting at polyamine synthesis (PACES/SWOG)⁴¹. Additionally, a review study showed that methionine dietary restriction can suppress tumor formation, potentially through reducing the availability of decarboxylated SAM which is a cofactor for spermidine (a polyamine) production⁴². Thus, the key metabolic pathways may have great applicability in sex-specific treatment or preventative interventions for CRC.

Some of the study limitations include the number of events in the cohorts compared to sample size, and the multiple categories such as three clinical stages, two sex groups, two anatomic locations, which might weaken statistical power. In addition, some potential confounders that may bias the results were not available in the clinical records for consideration in our analyses. Therefore, future studies from an independent cohort will be valuable.

In conclusion, we apply a novel methodology using tumor tissue to identify sex-specific metabolic pathways associated with CRC prognosis in a surgical cohort. We show that tumor metabolite levels have different associations with patient prognosis by sex, in particular ASNS-catalyzed asparagine production that are linked to poor prognosis only in females. Our study shows that sex-specific tumor metabolism is an important factor for understanding differences in patient prognosis and potentially differences in treatment responses. Accordingly, we

recommend that the design of precision medicine approaches consider both tumor metabolism and sex to obtain more robust findings in clinical trials and improve patient outcomes.

Acknowledgments

This work was funded by NIH 1R21CA223686-01 (CJ, SK) and American Cancer Society Research Scholar Grant 134273-RSG-20-065-01-TBE (CJ). This publication was also made possible by CTSA Grant Number UL1 TR001863 from the National Center for Advancing Translational Science (NCATS), components of the National Institutes of Health (NIH), and NIH roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH. This work was also supported by the Lampman Research Fund in Yale Surgical Oncology.

Table

Table 1. Demographic Characteristics and Clinical Factors.

Characteristics	No. of Patients	5-Year Overall Survival (OS)			5-Year Recurrence-free Survival (RFS)		
		Deaths, No.	Rate, % ^a	<i>P</i> Value ^b	Cases, No.	Rate, % ^a	<i>P</i> Value ^b
Age at diagnosis, y							
≤60	19	2	88.9	.048	3	84.2	.21
61-69	64	9	83.4		14	72.4	
70-79	81	15	78.7		12	81.4	
≥80	33	11	61.5		1	96.3	
Sex, n							
Male	102	23	74.3	.18	17	77.5	.48
Female	95	14	83.2		13	84.0	
Clinical stage, n							
I	47	3	92.5	.001	5	88.4	.09
II	86	13	82.4		11	82.0	
III	64	21	63.5		14	73.8	
Chemotherapy, n							
Yes	66	18	68.5	.03	15	73.1	.03
No	131	19	83.7		15	85.0	
Anatomic tumor location, n							
Left	99	17	81.2	.42	19	77.2	.23
Right	98	20	75.6		11	85.3	

^aSurvival rates were calculated by the Kaplan-Meier estimation method.

^b*P* value of Log-rank test.

Table 2. Multivariate analysis of asparagine synthesis catalyzed by asparagine synthetase (ASNS).

Prognosis	Sex	Model 1 ^a			Model 2 ^b		
		HR (95% CI) ^c	<i>P</i>	Interaction <i>P</i> value ^d	HR (95% CI) ^c	<i>P</i>	Interaction <i>P</i> value ^d
OS	Females	6.39 (1.78-22.91)	.004	.02	5.68 (1.06-30.61)	.04	.052
	Males	0.57 (0.36-0.91)	.02		0.46 (0.11-1.84)	.27	
RFS	Females	4.36 (1.39-3.68)	.01	.003	4.89 (1.07-22.39)	.04	.03
	Males	0.96 (0.61-1.50)	.86		1.15 (0.27-4.80)	.85	

^a Asparagine abundance was considered as a continuous variable (log₂ transformed).

^b Asparagine abundance was dichotomized to low levels (≤ 75% percentile of asparagine abundance among all patients) (reference) and high levels (> 75% percentile).

^c Hazard ratio for asparagine abundance in the corresponding multivariate Cox PH model, adjusted for anatomic location, clinical stages, chemotherapy history, age (continuous), and other crucial metabolites involved in ASNS-catalyzed asparagine synthesis (aspartate, glutamate, glutamine and AMP were treated as continuous variables and were log₂ transformed).

^d *P* values for the interaction between sex and asparagine.

Figure

Fig 1. Sex-specific differences in the associations between individual metabolite and CRC prognosis. (A) 5-year overall survival (OS) and (B) 5-year recurrence-free survival (RFS). LysoPC: Lysophosphatidylcholine. All metabolites were observed with significant sex interactions ($P_{\text{interaction}} < .05$). Hazard ratio (HR) for each metabolite (log₂-transformed abundance) was calculated by multivariate Cox PH regression adjusted for anatomic location, chemotherapy history, clinical stage, and age (continuous). Error bars represent 95% confidence intervals (CIs). 95% CIs marked with asterisks indicate significant associations between the metabolite and the corresponding prognosis (P values $< .05$): A metabolite with HR < 1 was associated with better prognosis; a metabolite with HR > 1 was associated with worse prognosis. The x-axes are log-scaled.

Fig 2. Cox Adjusted Survival Curves of ASNS-catalyzed asparagine. (A) OS of females, (B) OS of males, (C) RFS of females, and (D) RFS of males. Results were based on Model 2 (Table 2) using multivariate Cox PH regression, adjusted for anatomic location, chemotherapy history, clinical stages, age (continuous), and other crucial metabolites involved in ASNS-catalyzed asparagine synthesis (aspartate, glutamate, glutamine, and AMP were treated as continuous variables and were $\log_2$ transformed). P values for the associations between dichotomized asparagine levels and the prognosis in Model 2.

360 Reference List

- ¹ Colorectal cancer statistics. Centers for Disease Control and Prevention.
<https://www.cdc.gov/cancer/colorectal/statistics/index.htm>. Published June 8, 2021. Accessed October 13, 2021.
- ² Amin MB. *AJCC Cancer Staging Manual*. New York: Springer; 2017.
- ³ TNM classification of Malignant tumours. UICC. <https://www.uicc.org/resources/tnm>. Published July 21, 2021.
Accessed October 13, 2021.
- ⁴ Nakagawa-Senda H, Hori M, Matsuda T, Ito H. Prognostic impact of tumor location in colon cancer: The monitoring of cancer incidence in Japan (MCIJ) PROJECT. *BMC Cancer*. 2019;19(1). doi:10.1186/s12885-019-5644-y
- ⁵ Zheng C, Jiang F, Lin H, Li S. Clinical characteristics and prognosis of different primary tumor location in colorectal cancer: A population-based cohort study. *Clinical and Translational Oncology*. 2019;21(11):1524-1531. doi:10.1007/s12094-019-02083-1
- ⁶ Doleman B, Mills KT, Lim S, Zelhart MD, Gagliardi G. Body mass index and colorectal cancer prognosis: A systematic review and meta-analysis. *Techniques in Coloproctology*. 2016;20(8):517-535. doi:10.1007/s10151-016-1498-3
- ⁷ Zhu B, Wu X, Wu B, Pei D, Zhang L, Wei L. The relationship between diabetes and colorectal cancer prognosis: A meta-analysis based on the cohort studies. *PLOS ONE*. 2017;12(4). doi:10.1371/journal.pone.0176068
- ⁸ Xu G, Zhang M, Zhu H, Xu J. A 15-gene signature for prediction of colon cancer recurrence and prognosis based on SVM. *Gene*. 2017;604:33-40. doi:10.1016/j.gene.2016.12.016
- ⁹ Pietrzyk Ł, Korolczuk A, Matysek M, Arciszewski MB, Torres K. Clinical Value of Detecting Tumor Endothelial Marker 8 (ANTXR1) as a Biomarker in the Diagnosis and Prognosis of Colorectal Cancer. *Cancer Manag Res*. 2021;13:3113-3122. Published 2021 Apr 9. doi:10.2147/CMAR.S298165

-
- ¹⁰ Peng Q, Zhang X, Min M, Zou L, Shen P, Zhu Y. The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. *Oncotarget*. 2017;8(27):44893-44909. doi:10.18632/oncotarget.16488
- ¹¹ He T, Zhang M, Zheng R, et al. Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer. *Epigenomics*. 2017;9(6):849-862. doi:10.2217/epi-2017-0019
- ¹² Hsu CH, Hsiao CW, Sun CA, et al. Multiple gene promoter methylation and clinical stage in adjacent normal tissues: Effect on prognosis of colorectal cancer in Taiwan [published correction appears in Sci Rep. 2020 Feb 21;10(1):3550]. *Sci Rep*. 2020;10(1):145. Published 2020 Jan 10. doi:10.1038/s41598-019-56691-6
- ¹³ Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology. *CA Cancer J Clin*. 2021;71(4):333-358. doi:10.3322/caac.21670
- ¹⁴ Zhang F, Zhang Y, Zhao W, et al. Metabolomics for biomarker discovery in the diagnosis, prognosis, survival and recurrence of colorectal cancer: a systematic review. *Oncotarget*. 2017;8(21):35460-35472. doi:10.18632/oncotarget.16727
- ¹⁵ Ose J, Gigic B, Brezina S, et al. Targeted Plasma Metabolic Profiles and Risk of Recurrence in Stage II and III Colorectal Cancer Patients: Results from an International Cohort Consortium. *Metabolites*. 2021;11(3):129. Published 2021 Feb 24. doi:10.3390/metabo11030129
- ¹⁶ Berger MD, Yang D, Sunakawa Y, et al. Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. *Oncotarget*. 2016;7(33):53668-53678. doi:10.18632/oncotarget.10696
- ¹⁷ Abancens M, Bustos V, Harvey H, McBryan J, Harvey BJ. Sexual Dimorphism in Colon Cancer. *Front Oncol*. 2020;10:607909. Published 2020 Dec 9. doi:10.3389/fonc.2020.607909
- ¹⁸ Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2017;3(2):211-219. doi:10.1001/jamaoncol.2016.4227
- ¹⁹ Hansen IO, Jess P. Possible better long-term survival in left versus right-sided colon cancer - a systematic review. *Dan Med J*. 2012;59(6):A4444.

- ²⁰ Majek O, Gondos A, Jansen L, Emrich K, Holleczeck B, Katalinic A, et al. Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. *PLoS One*. 2013;8(7):e68077.
- ²¹ Cai Y, Rattray NJW, Zhang Q, et al. Sex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype. *Sci Rep*. 2020;10(1):4905. Published 2020 Mar 17. doi:10.1038/s41598-020-61851-0
- ²² Richards NG, Kilberg MS. Asparagine synthetase chemotherapy. *Annu Rev Biochem*. 2006;75:629-654. doi:10.1146/annurev.biochem.75.103004.142520
- ²³ Zhang J, Fan J, Venneti S, et al. Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. *Mol Cell*. 2014;56(2):205-218. doi:10.1016/j.molcel.2014.08.018
- ²⁴ Lin HH, Chung Y, Cheng CT, et al. Autophagic reliance promotes metabolic reprogramming in oncogenic KRAS-driven tumorigenesis. *Autophagy*. 2018;14(9):1481-1498. doi:10.1080/15548627.2018.1450708
- ²⁵ Krall AS, Xu S, Graeber TG, Braas D, Christofk HR. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. *Nat Commun*. 2016;7:11457. Published 2016 Apr 29. doi:10.1038/ncomms11457
- ²⁶ Knott SRV, Wagenblast E, Khan S, et al. Asparagine bioavailability governs metastasis in a model of breast cancer [published correction appears in Nature. 2018 Apr 4;556(7699):135]. *Nature*. 2018;554(7692):378-381. doi:10.1038/nature25465
- ²⁷ Du F, Chen J, Liu H, et al. SOX12 promotes colorectal cancer cell proliferation and metastasis by regulating asparagine synthesis. *Cell Death Dis*. 2019;10(3):239. Published 2019 Mar 11. doi:10.1038/s41419-019-1481-9
- ²⁸ Toda K, Kawada K, Iwamoto M, et al. Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase. *Neoplasia*. 2016;18(11):654-665. doi:10.1016/j.neo.2016.09.004
- ²⁹ Gwinn DM, Lee AG, Briones-Martin-Del-Campo M, et al. Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase. *Cancer Cell*. 2018;33(1):91-107.e6. doi:10.1016/j.ccell.2017.12.003

-
- ³⁰ Wong CC, Qian Y, Li X, et al. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate. *Gastroenterology*. 2016;151(5):945-960.e6. doi:10.1053/j.gastro.2016.07.011
- ³¹ Li X, Chung ACK, Li S, et al. LC-MS-based metabolomics revealed SLC25A22 as an essential regulator of aspartate-derived amino acids and polyamines in *KRAS*-mutant colorectal cancer. *Oncotarget*. 2017;8(60):101333-101344. Published 2017 Sep 20. doi:10.18632/oncotarget.21093
- ³² Hinze L, Labrosse R, Degar J, et al. Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy. *Cancer Discov*. 2020;10(11):1690-1705. doi:10.1158/2159-8290.CD-19-1472
- ³³ Chiu M, Taurino G, Bianchi MG, Kilberg MS, Bussolati O. Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia. *Front Oncol*. 2020;9:1480. Published 2020 Jan 9. doi:10.3389/fonc.2019.01480
- ³⁴ Montrose DC, Saha S, Foronda M, et al. Exogenous and Endogenous Sources of Serine Contribute to Colon Cancer Metabolism, Growth, and Resistance to 5-Fluorouracil. *Cancer Res*. 2021;81(9):2275-2288. doi:10.1158/0008-5472.CAN-20-1541
- ³⁵ Grant GA. D-3-Phosphoglycerate Dehydrogenase. *Front Mol Biosci*. 2018;5:110. Published 2018 Dec 13. doi:10.3389/fmolb.2018.00110
- ³⁶ Yoon S, Kim JG, Seo AN, et al. Clinical Implication of Serine Metabolism-Associated Enzymes in Colon Cancer. *Oncology*. 2015;89(6):351-359. doi:10.1159/000439571
- ³⁷ Bednarz-Misa I, Fleszar MG, Zawadzki M, et al. L-Arginine/NO Pathway Metabolites in Colorectal Cancer: Relevance as Disease Biomarkers and Predictors of Adverse Clinical Outcomes Following Surgery. *J Clin Med*. 2020;9(6):1782. Published 2020 Jun 8. doi:10.3390/jcm9061782
- ³⁸ Curis E, Nicolis I, Moinard C, et al. Almost all about citrulline in mammals. *Amino Acids*. 2005;29(3):177-205. doi:10.1007/s00726-005-0235-4
- ³⁹ Pegg AE. Regulation of ornithine decarboxylase. *J Biol Chem*. 2006;281(21):14529-14532. doi:10.1074/jbc.R500031200

⁴⁰ Laukaitis CM, Gerner EW. DFMO: targeted risk reduction therapy for colorectal neoplasia. *Best Pract Res Clin Gastroenterol.* 2011;25(4-5):495-506. doi:10.1016/j.bpg.2011.09.007

⁴¹ S0820, Adenoma and Second Primary Prevention Trial (PACES). ClinicalTrials.gov identifier: NCT01349881.

Updated February 25, 2021. Accessed October 13, 2021.

<https://clinicaltrials.gov/ct2/show/NCT01349881>

⁴² Wanders D, Hobson K, Ji X. Methionine Restriction and Cancer Biology. *Nutrients.* 2020;12(3):684. Published 2020 Mar 3. doi:10.3390/nu12030684